During the past 3 years, the average EPS without NRI Growth Rate was 4.90% per year.
During the past 5 years, the average EPS without NRI Growth Rate was -13.20% per year.
During the past 10 years, the average EPS without NRI Growth Rate was -57.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Relmada Therapeutics was 27.30% per year. The lowest was -785.80% per year. And the median was -26.05% per year.
Competitive Comparison of Relmada Therapeutics's 3-Year EPS without NRI Growth Rate
For the Biotechnology subindustry, Relmada Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Relmada Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Relmada Therapeutics's 3-Year EPS without NRI Growth Rate falls into.
Relmada Therapeutics 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
Relmada Therapeutics (NAS:RLMD) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Relmada Therapeutics 3-Year EPS without NRI Growth Rate Related Terms
Thank you for viewing the detailed overview of Relmada Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Relmada Therapeutics (Relmada Therapeutics) Business Description
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RLMD has been successfully added to your